# SAFETY DATA SHEET

## Neomycin Formulation

<table>
<thead>
<tr>
<th>Version</th>
<th>Revision Date:</th>
<th>SDS Number:</th>
<th>Date of last issue:</th>
<th>Date of first issue:</th>
</tr>
</thead>
<tbody>
<tr>
<td>2.0</td>
<td>04/04/2023</td>
<td>9404844-00006</td>
<td>12/16/2022</td>
<td>09/02/2021</td>
</tr>
</tbody>
</table>

## SECTION 1. IDENTIFICATION

**Product name**: Neomycin Formulation

**Manufacturer or supplier’s details**

- **Company name of supplier**: Merck & Co., Inc
- **Address**: 126 E. Lincoln Avenue, Rahway, New Jersey U.S.A. 07065
- **Telephone**: 908-740-4000
- **Emergency telephone**: 1-908-423-6000
- **E-mail address**: EHSDATASTEWARD@merck.com

**Recommended use of the chemical and restrictions on use**

- **Recommended use**: Veterinary product
- **Restrictions on use**: Not applicable

## SECTION 2. HAZARDS IDENTIFICATION

**GHS classification in accordance with the OSHA Hazard Communication Standard (29 CFR 1910.1200)**

- **Combustible dust**: Category 1
- **Skin sensitization**: Category 1
- **Reproductive toxicity**: Category 2
- **Specific target organ toxicity - repeated exposure**: Category 2 (Kidney, inner ear)

**GHS label elements**

- **Hazard pictograms**: ![Picture 1](image1.png) ![Picture 2](image2.png)
- **Signal Word**: Warning
- **Hazard Statements**: If small particles are generated during further processing, handling or by other means, may form combustible dust concentrations in air.
  - **H317**: May cause an allergic skin reaction.
  - **H361d**: Suspected of damaging the unborn child.
  - **H373**: May cause damage to organs (Kidney, inner ear) through prolonged or repeated exposure.

**Precautionary Statements**

- **Prevention**:
  - **P201**: Obtain special instructions before use.
  - **P202**: Do not handle until all safety precautions have been read and understood.
  - **P260**: Do not breathe dust.
  - **P272**: Contaminated work clothing must not be allowed out of...
SAFETY DATA SHEET

Neomycin Formulation

Version 2.0 Revision Date: 04/04/2023 SDS Number: 9404844-00006 Date of last issue: 12/16/2022 Date of first issue: 09/02/2021

the workplace.

P280 Wear protective gloves, protective clothing, eye protection and face protection.

Response:

P302 + P352 IF ON SKIN: Wash with plenty of soap and water.
P308 + P313 IF exposed or concerned: Get medical attention.
P333 + P313 If skin irritation or rash occurs: Get medical attention.
P363 Wash contaminated clothing before reuse.

Storage:

P405 Store locked up.

Disposal:

P501 Dispose of contents and container to an approved waste disposal plant.

Other hazards

Dust contact with the eyes can lead to mechanical irritation.
Contact with dust can cause mechanical irritation or drying of the skin.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

<table>
<thead>
<tr>
<th>Chemical name</th>
<th>CAS-No.</th>
<th>Concentration (% w/w)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neomycin, sulfate (salt)</td>
<td>1405-10-3</td>
<td>50</td>
</tr>
</tbody>
</table>

SECTION 4. FIRST AID MEASURES

General advice : In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical advice.

If inhaled : If inhaled, remove to fresh air.
Get medical attention.

In case of skin contact : In case of contact, immediately flush skin with soap and plenty of water.
Remove contaminated clothing and shoes.
Get medical attention.
Wash clothing before reuse.
Thoroughly clean shoes before reuse.

If swallowed : If swallowed, DO NOT induce vomiting.
Get medical attention.
Rinse mouth thoroughly with water.

Most important symptoms and effects, both acute and delayed : Contact with dust can cause mechanical irritation or drying of the skin.
Dust contact with the eyes can lead to mechanical irritation.
May cause an allergic skin reaction.
Suspected of damaging the unborn child. May cause damage to organs through prolonged or repeated exposure.

Protection of first-aiders: First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Notes to physician: Treat symptomatically and supportively.

SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media: Water spray
Alcohol-resistant foam
Carbon dioxide (CO2)
Dry chemical

Unsuitable extinguishing media: None known.

Specific hazards during firefighting: Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard. Exposure to combustion products may be a hazard to health.

Hazardous combustion products: Carbon oxides

Specific extinguishing methods: Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Use water spray to cool unopened containers.
Remove undamaged containers from fire area if it is safe to do so.
Evacuate area.

Special protective equipment for fire-fighters: In the event of fire, wear self-contained breathing apparatus.
Use personal protective equipment.

SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures: Use personal protective equipment.
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

Environmental precautions: Avoid release to the environment.
Prevent further leakage or spillage if safe to do so.
Retain and dispose of contaminated wash water.
Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up: Sweep up or vacuum up spillage and collect in suitable container for disposal.
Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).
Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to
determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

SECTION 7. HANDLING AND STORAGE

Technical measures: Static electricity may accumulate and ignite suspended dust causing an explosion. Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.

Local/Total ventilation: Use only with adequate ventilation.

Advice on safe handling: Do not get on skin or clothing. Do not breathe dust. Do not swallow. Avoid contact with eyes. Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment. Minimize dust generation and accumulation. Keep container closed when not in use. Keep away from heat and sources of ignition. Take precautionary measures against static discharges. Take care to prevent spills, waste and minimize release to the environment.

Conditions for safe storage: Keep in properly labeled containers. Store locked up. Store in accordance with the particular national regulations.

Materials to avoid: Do not store with the following product types: Strong oxidizing agents.

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Ingredients with workplace control parameters

<table>
<thead>
<tr>
<th>Inert or nuisance dust</th>
<th>50 Million particles per cubic foot</th>
</tr>
</thead>
<tbody>
<tr>
<td>Value type (Form of exposure): TWA (total dust)</td>
<td></td>
</tr>
<tr>
<td>Basis: OSHA Z-3</td>
<td></td>
</tr>
<tr>
<td>15 mg/m³</td>
<td></td>
</tr>
<tr>
<td>Value type (Form of exposure): TWA (total dust)</td>
<td></td>
</tr>
<tr>
<td>Basis: OSHA Z-3</td>
<td></td>
</tr>
<tr>
<td>5 mg/m³</td>
<td></td>
</tr>
<tr>
<td>Value type (Form of exposure): TWA (respirable fraction)</td>
<td></td>
</tr>
<tr>
<td>Basis: OSHA Z-3</td>
<td></td>
</tr>
<tr>
<td>15 Million particles per cubic foot</td>
<td></td>
</tr>
<tr>
<td>Value type (Form of exposure): TWA (respirable fraction)</td>
<td></td>
</tr>
<tr>
<td>Basis: OSHA Z-3</td>
<td></td>
</tr>
<tr>
<td>Dust, nuisance dust and particulates</td>
<td>10 mg/m³</td>
</tr>
<tr>
<td>Value type (Form of exposure): PEL (Total dust)</td>
<td></td>
</tr>
<tr>
<td>Basis: CAL PEL</td>
<td></td>
</tr>
</tbody>
</table>
SAFETY DATA SHEET

Neomycin Formulation

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Value type (Form of exposure)</th>
<th>Control parameters / Permissible concentration</th>
<th>Basis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neomycin, sulfate (salt)</td>
<td>1405-10-3</td>
<td>TWA</td>
<td>1 mg/m³ (OEB 1)</td>
<td>Internal</td>
</tr>
</tbody>
</table>

Further information: DSEN, OTO

Wipe limit 0.1 mg/100 cm² Internal

Engineering measures

Use feasible engineering controls to minimize exposure to compound. All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Personal protective equipment

Respiratory protection

General and local exhaust ventilation is recommended to maintain vapor exposures below recommended limits. Where concentrations are above recommended limits or are unknown, appropriate respiratory protection should be worn. Follow OSHA respirator regulations (29 CFR 1910.134) and use NIOSH/MSHA approved respirators. Protection provided by air purifying respirators against exposure to any hazardous chemical is limited. Use a positive pressure air supplied respirator if there is any potential for uncontrolled release, exposure levels are unknown, or any other circumstance where air purifying respirators may not provide adequate protection.

Hand protection

Material: Chemical-resistant gloves

Eye protection

Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Skin and body protection

Work uniform or laboratory coat.

Hygiene measures

If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Contaminated work clothing should not be allowed out of the workplace. Wash contaminated clothing before re-use. The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES
### Neomycin Formulation

<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Appearance</td>
<td>Powder</td>
</tr>
<tr>
<td>Color</td>
<td>White to light yellow</td>
</tr>
<tr>
<td>Odor</td>
<td>No data available</td>
</tr>
<tr>
<td>Odor Threshold</td>
<td>No data available</td>
</tr>
<tr>
<td>pH</td>
<td>No data available</td>
</tr>
<tr>
<td>Melting point/freezing point</td>
<td>No data available</td>
</tr>
<tr>
<td>Initial boiling point and boiling range</td>
<td>No data available</td>
</tr>
<tr>
<td>Flash point</td>
<td>Not applicable</td>
</tr>
<tr>
<td>Evaporation rate</td>
<td>Not applicable</td>
</tr>
<tr>
<td>Flammability (solid, gas)</td>
<td>May form combustible dust concentrations in air during processing, handling or other means.</td>
</tr>
<tr>
<td>Flammability (liquids)</td>
<td>Not applicable</td>
</tr>
<tr>
<td>Upper explosion limit / Upper flammability limit</td>
<td>No data available</td>
</tr>
<tr>
<td>Lower explosion limit / Lower flammability limit</td>
<td>No data available</td>
</tr>
<tr>
<td>Vapor pressure</td>
<td>Not applicable</td>
</tr>
<tr>
<td>Relative vapor density</td>
<td>Not applicable</td>
</tr>
<tr>
<td>Relative density</td>
<td>No data available</td>
</tr>
<tr>
<td>Density</td>
<td>No data available</td>
</tr>
<tr>
<td>Solubility(ies)</td>
<td></td>
</tr>
<tr>
<td>Water solubility</td>
<td>No data available</td>
</tr>
<tr>
<td>Partition coefficient: n-octanol/water</td>
<td>Not applicable</td>
</tr>
<tr>
<td>Autoignition temperature</td>
<td>No data available</td>
</tr>
<tr>
<td>Decomposition temperature</td>
<td>No data available</td>
</tr>
<tr>
<td>Viscosity</td>
<td></td>
</tr>
<tr>
<td>Viscosity, kinematic</td>
<td>Not applicable</td>
</tr>
<tr>
<td>Explosive properties</td>
<td>Not explosive</td>
</tr>
<tr>
<td>Oxidizing properties</td>
<td>The substance or mixture is not classified as oxidizing.</td>
</tr>
</tbody>
</table>
SECTION 10. STABILITY AND REACTIVITY

Reactivity: Not classified as a reactivity hazard.
Chemical stability: Stable under normal conditions.
Possibility of hazardous reactions: May form combustible dust concentrations in air during processing, handling or other means. Can react with strong oxidizing agents.

Conditions to avoid: Heat, flames and sparks. Avoid dust formation.
Incompatible materials: Oxidizing agents
Hazardous decomposition products: No hazardous decomposition products are known.

SECTION 11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure
Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity
Not classified based on available information.

Product:
Acute oral toxicity: Acute toxicity estimate: > 5,000 mg/kg
Method: Calculation method

Components:

Neomycin, sulfate (salt):

Acute oral toxicity
LD50 (Mouse): 2,880 mg/kg
LD50 (Rat): 2,750 mg/kg

Acute toxicity (other routes of administration)
LD50 (Rat): 633 mg/kg
Application Route: Subcutaneous
LD50 (Mouse): 116 mg/kg
Application Route: Intraperitoneal
LD50 (Mouse): 27.6 mg/kg
Application Route: Intravenous
LD50 (Mouse): 275 mg/kg
Application Route: Subcutaneous
SAFETY DATA SHEET

Neomycin Formulation

Skin corrosion/irritation
Not classified based on available information.

**Components:**

**Neomycin, sulfate (salt):**

<table>
<thead>
<tr>
<th>Species</th>
<th>Rabbit</th>
</tr>
</thead>
<tbody>
<tr>
<td>Result</td>
<td>Mild skin irritation</td>
</tr>
</tbody>
</table>

Serious eye damage/eye irritation
Not classified based on available information.

**Components:**

**Neomycin, sulfate (salt):**

<table>
<thead>
<tr>
<th>Species</th>
<th>Rabbit</th>
</tr>
</thead>
<tbody>
<tr>
<td>Result</td>
<td>No eye irritation</td>
</tr>
</tbody>
</table>

Respiratory or skin sensitization

Skin sensitization
May cause an allergic skin reaction.

Respiratory sensitization
Not classified based on available information.

**Components:**

**Neomycin, sulfate (salt):**

<table>
<thead>
<tr>
<th>Routes of exposure</th>
<th>Dermal</th>
</tr>
</thead>
<tbody>
<tr>
<td>Species</td>
<td>Humans</td>
</tr>
<tr>
<td>Result</td>
<td>positive</td>
</tr>
</tbody>
</table>

Germ cell mutagenicity
Not classified based on available information.

**Components:**

**Neomycin, sulfate (salt):**

<table>
<thead>
<tr>
<th>Genotoxicity in vitro</th>
<th>Test Type: Bacterial reverse mutation assay (AMES) Result: negative</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Test Type: In vitro mammalian cell gene mutation test Result: negative</td>
</tr>
<tr>
<td></td>
<td>Test Type: Chromosomal aberration Test system: Human lymphocytes Result: positive</td>
</tr>
<tr>
<td></td>
<td>Test Type: in vitro micronucleus test Result: negative</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Genotoxicity in vivo</th>
<th>Test Type: Cytogenetic assay Species: Mouse</th>
</tr>
</thead>
</table>
SAFETY DATA SHEET

Neomycin Formulation

Cell type: Bone marrow
Application Route: Intravenous injection
Result: negative

Carcinogenicity
Not classified based on available information.

Components:
Neomycin, sulfate (salt):
Species: Rat
Exposure time: 2 Years
Result: negative

IARC
No ingredient of this product present at levels greater than or equal to 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.

OSHA
No component of this product present at levels greater than or equal to 0.1% is on OSHA’s list of regulated carcinogens.

NTP
No ingredient of this product present at levels greater than or equal to 0.1% is identified as a known or anticipated carcinogen by NTP.

Reproductive toxicity
Suspected of damaging the unborn child.

Components:
Neomycin, sulfate (salt):
Effects on fertility: Test Type: Three-generation reproduction toxicity study
Species: Rat
Application Route: Oral
General Toxicity Parent: NOAEL: 25 mg/kg body weight
Result: No effects on fertility and early embryonic development were detected.

Effects on fetal development: Test Type: Embryo-fetal development
Species: Rat
Application Route: Oral
Embryo-fetal toxicity: NOAEL: 275 mg/kg body weight
Result: No adverse effects, No teratogenic effects.

Test Type: Development
Species: Rat
Application Route: Subcutaneous
Developmental Toxicity: LOAEL: 6 mg/kg body weight
Result: positive

Reproductive toxicity - Assessment: Some evidence of adverse effects on development, based on animal experiments.

STOT-single exposure
Not classified based on available information.
STOT-repeated exposure
May cause damage to organs (Kidney, inner ear) through prolonged or repeated exposure.

**Components:**

**Neomycin, sulfate (salt):**

<table>
<thead>
<tr>
<th>Target Organs</th>
<th>Assessment</th>
<th>Remarks</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kidney, inner ear</td>
<td>May cause damage to organs through prolonged or repeated exposure.</td>
<td>Based on human experience.</td>
</tr>
</tbody>
</table>

**Repeated dose toxicity**

**Components:**

**Neomycin, sulfate (salt):**

<table>
<thead>
<tr>
<th>Species</th>
<th>LOAEL</th>
<th>Application Route</th>
<th>Exposure time</th>
<th>Target Organs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mouse</td>
<td>30 mg/kg</td>
<td>Subcutaneous</td>
<td>14 d</td>
<td>Kidney</td>
</tr>
<tr>
<td>Guinea pig</td>
<td>50 mg/kg</td>
<td>Intramuscular</td>
<td>30 - 60 Weeks</td>
<td>Kidney</td>
</tr>
<tr>
<td>Guinea pig</td>
<td>100 mg/kg</td>
<td>Oral</td>
<td></td>
<td>ear</td>
</tr>
<tr>
<td>Guinea pig</td>
<td>10 mg/kg</td>
<td>Oral</td>
<td>90 d</td>
<td>ear</td>
</tr>
<tr>
<td>Guinea pig</td>
<td>100 mg/kg</td>
<td>Subcutaneous</td>
<td>34 d</td>
<td>ear</td>
</tr>
<tr>
<td>Dog</td>
<td>24 mg/kg</td>
<td>Intramuscular</td>
<td>30 d</td>
<td>Kidney</td>
</tr>
<tr>
<td>Rat</td>
<td>25 mg/kg</td>
<td>oral (feed)</td>
<td>84 Weeks</td>
<td>ear</td>
</tr>
<tr>
<td>Dog</td>
<td></td>
<td></td>
<td></td>
<td>hearing loss</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>mortality observed</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Species</th>
<th>LOAEL</th>
<th>Application Route</th>
<th>Exposure time</th>
<th>Target Organs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dog</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Symptoms:**

- hearing loss
- mortality observed
SAFETY DATA SHEET
Neomycin Formulation

Version 2.0  Revision Date: 04/04/2023  SDS Number: 9404844-00006  Date of last issue: 12/16/2022  Date of first issue: 09/02/2021

<table>
<thead>
<tr>
<th>LOAEL</th>
<th>20 mg/kg</th>
</tr>
</thead>
<tbody>
<tr>
<td>Application Route</td>
<td>Subcutaneous</td>
</tr>
<tr>
<td>Exposure time</td>
<td>90 d</td>
</tr>
<tr>
<td>Target Organs</td>
<td>Kidney</td>
</tr>
</tbody>
</table>

Aspiration toxicity
Not classified based on available information.

Experience with human exposure

Components:
Neomycin, sulfate (salt):

<table>
<thead>
<tr>
<th>Skin contact</th>
<th>Symptoms: Sensitization</th>
</tr>
</thead>
<tbody>
<tr>
<td>Remarks: May irritate skin.</td>
<td></td>
</tr>
</tbody>
</table>

| Eye contact | Remarks: May cause eye irritation. |

| Ingestion | Symptoms: Nausea, Vomiting, Diarrhea, tinnitus, hearing loss, Loss of balance |

SECTION 12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:
Neomycin, sulfate (salt):

| Toxicity to daphnia and other aquatic invertebrates | EC50 (Daphnia magna (Water flea)): > 72 mg/l |
| Exposure time: 48 h |
| Method: OECD Test Guideline 202 |

| LC50 (Americamysis): 39 mg/l |
| Exposure time: 96 h |
| Method: US-EPA OPPTS 850.1035 |

| Toxicity to algae/aquatic plants | EC50 (Anabaena flos-aquae (cyanobacterium)): 0.00075 mg/l |
| Exposure time: 72 h |
| Method: OECD Test Guideline 201 |

| NOEC (Anabaena flos-aquae (cyanobacterium)): 0.0003 mg/l |
| Exposure time: 72 h |
| Method: OECD Test Guideline 201 |

| EC50 (Pseudokirchneriella subcapitata (green algae)): 0.0099 mg/l |
| Exposure time: 72 h |
| Method: OECD Test Guideline 201 |

| NOEC (Pseudokirchneriella subcapitata (green algae)): 0.0022 mg/l |
| Exposure time: 72 h |
| Method: OECD Test Guideline 201 |

| Toxicity to microorganisms | EC50 (Natural microorganism): 107.6 mg/l |
| Exposure time: 3 h |
| Test Type: Respiration inhibition |
SAFETY DATA SHEET

Neomycin Formulation

Version: 2.0    Revision Date: 04/04/2023    SDS Number: 9404844-00006    Date of last issue: 12/16/2022
Date of first issue: 09/02/2021

Method: OECD Test Guideline 209

EC10 (Natural microorganism): 2.8 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209

Persistence and degradability

Components:

Neomycin, sulfate (salt):

Biodegradability: Result: rapidly degradable
Biodegradation: 50 %
Exposure time: 1.2 d
Method: OECD Test Guideline 314

Bioaccumulative potential

Components:

Neomycin, sulfate (salt):

Partition coefficient: n-octanol/water: log Pow: < -2

Mobility in soil:
No data available

Other adverse effects:
No data available

SECTION 13. DISPOSAL CONSIDERATIONS

Disposal methods

Waste from residues: Dispose of in accordance with local regulations.
Do not dispose of waste into sewer.
Contaminated packaging: Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

SECTION 14. TRANSPORT INFORMATION

International Regulations

UNRTDG
UN number: UN 3077
Proper shipping name: ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Neomycin, sulfate (salt))
Class: 9
Packing group: III
Labels: 9

IATA-DGR
UN/ID No.: UN 3077
# SAFETY DATA SHEET

## Neomycin Formulation

<table>
<thead>
<tr>
<th>Version</th>
<th>Revision Date:</th>
<th>SDS Number:</th>
<th>Date of last issue:</th>
<th>Date of first issue:</th>
</tr>
</thead>
<tbody>
<tr>
<td>2.0</td>
<td>04/04/2023</td>
<td>9404844-00006</td>
<td>12/16/2022</td>
<td>09/02/2021</td>
</tr>
</tbody>
</table>

- **Proper shipping name**: Environmentally hazardous substance, solid, n.o.s. (Neomycin, sulfate (salt))
- **Class**: 9
- **Packing group**: III
- **Labels**: Miscellaneous
- **Packing instruction (cargo aircraft)**: 956
- **Packing instruction (passenger aircraft)**: 956
- **Environmentally hazardous**: yes

### IMDG-Code
- **UN number**: UN 3077
- **Proper shipping name**: ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Neomycin, sulfate (salt))
- **Class**: 9
- **Packing group**: III
- **Labels**: 9
- **EmS Code**: F-A, S-F
- **Marine pollutant**: yes

### Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code
Not applicable for product as supplied.

### Domestic regulation

#### 49 CFR
- **UN/ID/NA number**: UN 3077
- **Proper shipping name**: Environmentally hazardous substance, solid, n.o.s. (Neomycin, sulfate (salt))
- **Class**: 9
- **Packing group**: III
- **Labels**: CLASS 9
- **ERG Code**: 171
- **Marine pollutant**: yes (Neomycin, sulfate (salt))
- **Remarks**: Above applies only to containers over 119 gallons or 450 liters. Shipment by ground under DOT is non-regulated; however it may be shipped per the applicable hazard classification to facilitate multi-modal transport involving ICAO (IATA) or IMO.

### Special precautions for user
The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

## SECTION 15. REGULATORY INFORMATION

### CERCLA Reportable Quantity
This material does not contain any components with a CERCLA RQ.

### SARA 304 Extremely Hazardous Substances Reportable Quantity
This material does not contain any components with a section 304 EHS RQ.
SARA 302 Extremely Hazardous Substances Threshold Planning Quantity
This material does not contain any components with a section 302 EHS TPQ.

SARA 311/312 Hazards:
- Combustible dust
- Respiratory or skin sensitization
- Reproductive toxicity
- Specific target organ toxicity (single or repeated exposure)

SARA 313:
This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.

US State Regulations

Pennsylvania Right To Know
- Lactose 63-42-3
- Neomycin, sulfate (salt) 1405-10-3

California Prop. 65
WARNING: This product can expose you to chemicals including Neomycin, sulfate (salt), which is/are known to the State of California to cause birth defects or other reproductive harm. For more information go to www.P65Warnings.ca.gov.

The ingredients of this product are reported in the following inventories:
- AICS: not determined
- DSL: not determined
- IECSC: not determined

SECTION 16. OTHER INFORMATION

Further information
HMIS® ratings are based on a 0-4 rating scale, with 0 representing minimal hazards or risks, and 4 representing significant hazards or risks. The "*" represents a chronic hazard, while the "/" represents the absence of a chronic hazard.

**Full text of other abbreviations**

- CAL PEL: California permissible exposure limits for chemical contaminants (Title 8, Article 107)
- OSHA Z-3: USA. Occupational Exposure Limits (OSHA) - Table Z-3 Mineral Dusts
- CAL PEL / PEL: Permissible exposure limit
- OSHA Z-3 / TWA: 8-hour time weighted average

ACGIH - American Conference of Governmental Industrial Hygienists; AGS - Allergic contact dermatitis; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CERCLA - Comprehensive Environmental Response, Compensation, and Liability Act; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DOT - Department of Transportation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; EHS - Extremely Hazardous Substance; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; HMIS - Hazardous Materials Identification System; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECS - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50% of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; MSHA - Mine Safety and Health Administration; n.o.s. - Not Otherwise Specified; NFPA - National Fire Protection Association; NO(A)EL - No Observed (Adverse) Effect Loading Rate; NOELR - No Observable Effect Loading Rate; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; RCRA - Resource Conservation and Recovery Act; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concern-
SAFETY DATA SHEET

Neomycin Formulation

Version 2.0  Revision Date: 04/04/2023  SDS Number: 9404844-00006  Date of last issue: 12/16/2022  Date of first issue: 09/02/2021


Revision Date: 04/04/2023

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user’s end product, if applicable.

US / Z8